目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 YEARS CONSIDERED
1.4.2 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 MARKET SIZE ASSESSMENT, SEGMENT LEVEL
2.3 MARKET GROWTH FORECAST
2.4 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME ESTIMATION
2.5 MARKET BREAKDOWN & DATA TRIANGULATION
2.6 STUDY ASSUMPTIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW
4.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION & COUNTRY (2024)
4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2025 VS. 2030
4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2024
4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing use of synthesized oligos in therapeutic & diagnostic applications
5.2.1.2 Technological advancements
5.2.1.3 Growing government investments in life science research & synthetic biology
5.2.1.4 Growing focus on precision/personalized medicine
5.2.2 RESTRAINTS
5.2.2.1 Complexities associated with therapeutic oligonucleotides
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing R&D investments by key players in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Lack of standard regulations
5.2.4.2 Delivery of oligonucleotide drugs to specific targets
5.3 INDUSTRY TRENDS
5.3.1 GROWING FOCUS ON DEVELOPMENT OF DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS
5.3.2 GROWING FOCUS ON TECHNOLOGY DEVELOPMENT FOR SUSTAINABLE & LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES
5.3.3 FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION
5.3.4 GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL & RARE DISEASES
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.6.1 ROLE IN ECOSYSTEM
5.7 TECHNOLOGY ANALYSIS
5.7.1 KEY TECHNOLOGIES
5.7.1.1 Solid-phase synthesis
5.7.1.2 Liquid-phase synthesis
5.7.1.3 Enzymatic oligo synthesis
5.7.2 COMPLEMENTARY TECHNOLOGIES
5.7.2.1 Polymerase chain reaction (PCR)
5.7.2.2 Next-generation sequencing
5.7.2.3 Microarray analysis
5.7.3 ADJACENT TECHNOLOGIES
5.7.3.1 CRISPR
5.7.3.2 Lipid nanoparticles
5.8 PRICING ANALYSIS
5.8.1 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022-2024
5.8.2 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, 2022-2024
5.8.3 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYERS, 2022-2024
5.8.4 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY REGION, 2024
5.8.5 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2024
5.8.6 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2024
5.9 PATENT ANALYSIS
5.9.1 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
5.10 PIPELINE ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA (HS CODE 293499)
5.11.2 EXPORT DATA (HS CODE 293499)
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 TARIFF & REGULATORY LANDSCAPE
5.13.1 TARIFF DATA (HS CODE 2934.99, 3822.00)
5.13.1.1 Trade policy updates affecting oligonucleotide synthesis market, 2022-2025
5.13.1.2 Impact of Tariffs on pricing & supply chain
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
5.13.3 REGULATORY FRAMEWORK
5.14 PORTER'S FIVE FORCES ANALYSIS
5.14.1 DEGREE OF COMPETITION
5.14.2 BARGAINING POWER OF SUPPLIERS
5.14.3 BARGAINING POWER OF BUYERS
5.14.4 THREAT OF SUBSTITUTES
5.14.5 THREAT OF NEW ENTRANTS
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 BUYING CRITERIA FOR END USERS
5.16 CASE STUDY ANALYSIS
5.16.1 CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT
5.16.2 CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING
5.16.3 CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA
5.17 INVESTMENT/FUNDING SCENARIO
5.18 IMPACT OF GENERATIVE AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET
5.19 TRUMP TARIFF IMPACT OVERVIEW: OLIGONUCLEOTIDE SYNTHESIS MARKET
5.19.1 KEY TARIFF RATES
5.19.2 PRICE IMPACT ANALYSIS
5.19.3 KEY IMPACT ON VARIOUS REGIONS
5.19.3.1 US
5.19.3.2 Europe
5.19.3.3 APAC
5.19.3.4 Rest of the World
5.19.4 END-USE INDUSTRY IMPACT
5.19.4.1 Hospitals
5.19.4.2 Pharmaceutical & biotechnology companies
5.19.4.3 Diagnostic laboratories
5.19.4.4 CROs & CDMOs
5.19.4.5 Academic & research institutes

6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 OLIGONUCLEOTIDE-BASED DRUGS
6.2.1 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
6.2.1.1 Antisense oligonucleotide-based drugs
6.2.1.1.1 Growing use of antisense oligos in oligonucleotide-based drugs to boost growth
6.2.1.2 siRNA oligonucleotide-based drugs
6.2.1.2.1 Large pipeline of products to favor market growth
6.2.1.3 Other oligonucleotide-based drugs
6.3 SYNTHESIZED OLIGONUCLEOTIDES
6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
6.3.1.1 Primers
6.3.1.1.1 Increasing applications of oligo primers in DNA sequencing and molecular diagnostics to drive growth
6.3.1.2 Probes
6.3.1.2.1 Advancements in molecular diagnostic technologies such as FISH and qPCR to support market growth
6.3.1.3 DNA oligonucleotides
6.3.1.3.1 Diverse usage of DNA oligos to support market growth
6.3.1.4 RNA oligonucleotides
6.3.1.4.1 Growing diagnostic and therapeutic applications of RNA oligos to propel growth
6.3.1.5 Other synthesized oligonucleotides
6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
6.3.2.1 Custom oligonucleotides
6.3.2.1.1 Increasing demand for custom oligonucleotides for therapeutic research studies to drive growth
6.3.2.2 Predesigned oligonucleotides
6.3.2.2.1 Ability of predesigned oligos to save time required in design and optimization to boost adoption
6.4 REAGENTS & CONSUMABLES
6.4.1 GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS
6.5 EQUIPMENT
6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET

7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 THERAPEUTIC APPLICATIONS
7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
7.2.1.1 Neurological disorders
7.2.1.1.1 Growing research on oligonucleotide-based drugs for treatment of DMD and SMA to drive market
7.2.1.2 Rare diseases
7.2.1.2.1 High specificity & efficacy of oligo-based drugs against rare diseases to support growth
7.2.1.3 Other diseases
7.3 RESEARCH APPLICATIONS
7.3.1 PCR
7.3.1.1 Increasing use of PCR in molecular biology research to drive market
7.3.2 SEQUENCING
7.3.2.1 Advancements in sequencing technologies & low cost of DNA sequencing to boost market
7.3.3 OTHER RESEARCH APPLICATIONS
7.4 DIAGNOSTIC APPLICATIONS
7.4.1 INCREASING DEMAND FOR RAPID & SPECIFIC METHODS FOR DISEASE DETECTION SUPPORT MARKET GROWTH

8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS
8.2.1 INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO PROPEL MARKET
8.4 DIAGNOSTIC LABORATORIES
8.4.1 RISING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO FUEL MARKET
8.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO SUPPORT MARKET GROWTH
8.6 ACADEMIC RESEARCH INSTITUTES
8.6.1 GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET

9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
9.2.2 US
9.2.2.1 Government initiatives and strategic developments by leading players to drive market
9.2.3 CANADA
9.2.3.1 Strong research infrastructure and availability of funding to support market growth
9.3 EUROPE
9.3.1 EUROPE: MACROECONOMIC OUTLOOK
9.3.2 GERMANY
9.3.2.1 Government & private funding investments towards health research to drive market
9.3.3 UK
9.3.3.1 Strategic collaborations & partnerships between key market players to fuel market
9.3.4 FRANCE
9.3.4.1 Favorable government initiatives for genomics research to boost demand
9.3.5 ITALY
9.3.5.1 Increasing R&D expenditure for pharma & biotech companies to support market growth
9.3.6 SPAIN
9.3.6.1 Favorable funding investments for biomedical research to drive market
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
9.4.2 CHINA
9.4.2.1 Expansion of leading pharmaceutical & biotechnology companies to drive market
9.4.3 JAPAN
9.4.3.1 Growing research initiatives & strategic developments to boost demand
9.4.4 INDIA
9.4.4.1 Development of bioclusters and improvements in healthcare infrastructure to propel market
9.4.5 AUSTRALIA
9.4.5.1 Increasing government initiatives and research funding to support market growth
9.4.6 SOUTH KOREA
9.4.6.1 Growing research activities and strategic expansions in oligonucleotide synthesis to aid market
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
9.5.2 BRAZIL
9.5.2.1 Availability of leading oligo-based therapies to support market growth
9.5.3 MEXICO
9.5.3.1 Growing adoption of NGS technology to drive market
9.5.4 ARGENTINA
9.5.4.1 Increasing research collaborations and government support to boost market
9.5.5 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
9.6.2 GCC COUNTRIES
9.6.2.1 Saudi Arabia (KSA)
9.6.2.1.1 Increasing focus on research & government support to propel market
9.6.2.2 United Arab Emirates (UAE)
9.6.2.2.1 Growing focus on life sciences research to fuel market
9.6.2.3 Other GCC countries
9.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
9.7.2 AFRICA: MACROECONOMIC OUTLOOK

10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.3 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.3.1 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022-2024
10.3.2 REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2022-2024
10.4 MARKET SHARE ANALYSIS
10.4.1 MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
10.4.2 MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS),2024
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024
10.6.1 STARS
10.6.2 EMERGING LEADERS
10.6.3 PERVASIVE PLAYERS
10.6.4 PARTICIPANTS
10.6.5 COMPANY FOOTPRINT:
10.6.5.1 Company footprint (Research & diagnostic applications)
10.6.5.2 Region footprint (Research & diagnostic applications)
10.6.5.3 Product footprint (Research & diagnostic applications)
10.6.5.4 Application footprint (Research & diagnostic applications)
10.6.5.5 Company footprint (Therapeutic applications)
10.6.5.6 Region footprint (Therapeutic applications)
10.6.5.7 Product footprint (Therapeutic applications)
10.6.5.8 Application footprint (Therapeutic applications)
10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.7.1 PROGRESSIVE COMPANIES
10.7.2 RESPONSIVE COMPANIES
10.7.3 DYNAMIC COMPANIES
10.7.4 STARTING BLOCKS
10.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.7.5.1 Detailed list of key startups/SMEs
10.7.5.2 Competitive benchmarking of startups/SMEs
10.8 COMPANY VALUATION & FINANCIAL METRICS
10.8.1 FINANCIAL METRICS (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.8.2 COMPANY VALUATION (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.8.3 FINANCIAL METRICS (THERAPEUTIC APPLICATIONS)
10.8.4 COMPANY VALUATION (THERAPEUTIC APPLICATIONS)
10.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
10.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH & DIAGNOSTIC APPLICATIONS)
10.9.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS)
10.10 COMPETITIVE SCENARIO
10.10.1 PRODUCT APPROVALS

11 COMPANY PROFILES
11.1 KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS)
11.1.1 DANAHER CORPORATION
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Deals
11.1.1.3.2 Expansions
11.1.1.3.3 Other developments
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses & competitive threats
11.1.2 THERMO FISHER SCIENTIFIC INC.
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Deals
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses & competitive threats
11.1.3 MERCK KGAA
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Deals
11.1.3.3.2 Expansions
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses & competitive threats
11.1.4 LGC LIMITED
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 Recent developments
11.1.4.3.1 Deals
11.1.4.3.2 Expansions
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses & competitive threats
11.1.5 EUROFINS SCIENTIFIC
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 Recent developments
11.1.5.3.1 Deals
11.1.5.3.2 Expansions
11.1.5.4 MnM view
11.1.5.4.1 Key strengths
11.1.5.4.2 Strategic choices
11.1.5.4.3 Weaknesses & competitive threats
11.1.6 AGILENT TECHNOLOGIES, INC.
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Deals
11.1.6.3.2 Expansions
11.1.7 KANEKA CORPORATION
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.7.3 Recent developments
11.1.7.3.1 Expansions
11.1.8 MARAVAI LIFESCIENCES
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.8.3.2 Expansions
11.1.9 AZENTA US INC.
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.10 TWIST BIOSCIENCE
11.1.10.1 Business overview
11.1.10.2 Products offered
11.1.10.3 Recent developments
11.1.10.3.1 Deals
11.1.11 GENSCRIPT
11.1.11.1 Business overview
11.1.11.2 Products offered
11.1.11.3 Recent developments
11.1.11.3.1 Deals
11.1.11.3.2 Expansions
11.2 KEY PLAYERS (THERAPEUTIC APPLICATIONS)
11.2.1 BIOGEN
11.2.1.1 Business overview
11.2.1.2 Products offered
11.2.1.3 Recent developments
11.2.1.3.1 Product approvals
11.2.1.3.2 Deals
11.2.1.3.3 Expansions
11.2.1.4 MnM view
11.2.1.4.1 Key strengths
11.2.1.4.2 Strategic choices
11.2.1.4.3 Weaknesses & competitive threats
11.2.2 ALNYLAM PHARMACEUTICALS, INC.
11.2.2.1 Business overview
11.2.2.2 Products offered
11.2.2.3 Recent developments
11.2.2.3.1 Product approvals
11.2.2.3.2 Deals
11.2.2.4 MnM view
11.2.2.4.1 Key strengths
11.2.2.4.2 Strategic choices
11.2.2.4.3 Weaknesses & competitive threats
11.2.3 SAREPTA THERAPEUTICS, INC.
11.2.3.1 Business overview
11.2.3.2 Products offered
11.2.3.3 Recent developments
11.2.3.3.1 Product approvals
11.2.3.3.2 Expansions
11.2.3.4 MnM view
11.2.3.4.1 Key strengths
11.2.3.4.2 Strategic choices
11.2.3.4.3 Weaknesses & competitive threats
11.2.4 ASTRAZENECA
11.2.4.1 Business overview
11.2.4.2 Products offered
11.2.4.3 Recent developments
11.2.4.3.1 Deals
11.2.4.3.2 Product Approvals
11.2.4.4 MnM view
11.2.4.4.1 Key strengths
11.2.4.4.2 Strategic choices
11.2.4.4.3 Weaknesses & competitive threats
11.2.5 ASTELLAS PHARMA INC.
11.2.5.1 Business overview
11.2.5.2 Products offered
11.2.5.3 Recent developments
11.2.5.3.1 Deals
11.2.5.3.2 Product approvals
11.2.5.4 MnM view
11.2.5.4.1 Key strengths
11.2.5.4.2 Strategic choices
11.2.5.4.3 Weaknesses & competitive threats
11.2.6 JAZZ PHARMACEUTICALS PLC
11.2.6.1 Business overview
11.2.6.2 Products offered
11.2.7 NIPPON SHINYAKU, CO. LTD.
11.2.7.1 Business overview
11.2.7.2 Products offered
11.2.7.3 Recent developments
11.2.7.3.1 Deals
11.2.8 IONIS PHARMACEUTICALS, INC.
11.2.8.1 Business overview
11.2.8.2 Products offered
11.2.8.3 Recent developments
11.2.8.3.1 Product Approvals
11.2.8.3.2 Deals
11.2.9 NOVARTIS AG
11.2.9.1 Business overview
11.2.9.2 Products offered
11.2.9.3 Recent developments
11.2.9.3.1 Product Approvals
11.2.9.3.2 Deals
11.3 OTHER PLAYERS
11.3.1 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
11.3.2 BIOLEGIO B.V.
11.3.3 BIOLYTIC LAB PERFORMANCE, INC.
11.3.4 BIOCOMMA LIMITED
11.3.5 REVVITY (SUBSIDIARY OF HORIZON DISCOVERY LTD.)
11.3.6 BIO-SYNTHESIS, INC.
11.3.7 CREATIVE BIOGENE
11.3.8 REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE)

12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS